share_log

德琪醫藥-B:自願公告 用於治療晚期實體瘤患者的小分子ERK1/2抑制劑ATG-017的I期試驗獲美國FDA的IND許可

ANTENGENE-B: VOLUNTARY ANNOUNCEMENT U.S. FDA IND CLEARANCE FOR PHASE I TRIAL OF SMALL MOLECULE ERK1/2 INHIBITOR ATG-017 IN PATIENTS WITH ADVANCED SOLID TUMORS

Oct 31, 2022 08:00
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more